Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 16;110(3):163–172. doi: 10.1093/trstmh/trv107

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — WHO recommended groupings of multidrug-resistant TB (MDR-TB) drugs.

^aThere are high rates of streptomycin resistance in MDR-TB strains; it is not considered a second line anti-TB injectable agent. ^bGatifloxacin may have side-effects including dysglycaemia. It has been removed from the market in several countries. Early generation fluoroquinolones do not high adequate activity against MDR-TB. ^cTerizidone may also be listed as Group 4 anti-TB drug. It has limited programmatic and efficacy data compared to the others. ^dOther Group 5 drugs, with variable in vitro and animal data to support use include amoxicillin/calvulanate, imipenem/cilastatin, meropenem, thioacetazone and clarithromycin.